Table 1.

Baseline characteristics of included patients

	N (total n = 28)
Age (mean; SD)	49 (±15)
Sex
Male	17 (60.7%)
Female	11 (39.3%)
WHO grade
II	11 (39.3%)
III	7 (25%)
IV	10 (35.7%)
Tumor type
Astrocytoma	13 (46.4%)
Oligodendroglioma	3 (10.7%)
Mixed	1 (3.6%)
Ganglioglioma	1 (3.6%)
Glioblastoma	10 (35.7%)
Prescribed dose
28 × 1.8 = 50.4 Gy	11 (39.3%)
30 × 1.8 = 54 Gy	2 (7.1%)
30 × 20 = 60 Gy	15 (53.6%)
Chemotherapy
None	4 (14.3%)
Temozolomide	20 (71.4%)
PCV	4 (14.3%)

PCV, procarbazine, lomustine, and vincristine.